On December 28, 2019, just as news of the Wuhan plague sank its teeth into American society, Pfizer CEO Albert Bourla confronted then-FDA director Stephen Hahn with what he described as an intractable dilemma: Bourla lamented Pfizer’s “revenue loss,” a curious choice of words to describe a pharmaceutical manufacturer that netted $16.7 billion in 2019, … Continue reading Pfizer, the FDA, and Bribes Aplenty